Chagas Disease (American Trypanosomiasis) R&D Pipeline Analysis Report, Q4 2020
Chagas Disease (American Trypanosomiasis) Pipeline Overview
The Q4 Chagas Disease (American Trypanosomiasis) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Chagas Disease (American Trypanosomiasis), provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Chagas Disease (American Trypanosomiasis) Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Chagas Disease (American Trypanosomiasis) disease overview, Chagas Disease (American Trypanosomiasis) types, Chagas Disease (American Trypanosomiasis) symptoms, causes, and FDA/EMA approved treatment options.
Chagas Disease (American Trypanosomiasis) Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Chagas Disease (American Trypanosomiasis) indication. The report presents near-term and long-term pipeline development trends and potential insights.
Chagas Disease (American Trypanosomiasis) Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 14 companies. Business profiles and contact details of the companies actively perusing Chagas Disease (American Trypanosomiasis) pipeline are assessed.
Chagas Disease (American Trypanosomiasis) R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Chagas Disease (American Trypanosomiasis) discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Chagas Disease (American Trypanosomiasis) companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Chagas Disease (American Trypanosomiasis) pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Chagas Disease (American Trypanosomiasis) Pipeline Market News and Developments during 2020
The Chagas Disease (American Trypanosomiasis) industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Chagas Disease (American Trypanosomiasis) Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
The Q4 Chagas Disease (American Trypanosomiasis) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Chagas Disease (American Trypanosomiasis), provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Chagas Disease (American Trypanosomiasis) Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Chagas Disease (American Trypanosomiasis) disease overview, Chagas Disease (American Trypanosomiasis) types, Chagas Disease (American Trypanosomiasis) symptoms, causes, and FDA/EMA approved treatment options.
Chagas Disease (American Trypanosomiasis) Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Chagas Disease (American Trypanosomiasis) indication. The report presents near-term and long-term pipeline development trends and potential insights.
Chagas Disease (American Trypanosomiasis) Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 14 companies. Business profiles and contact details of the companies actively perusing Chagas Disease (American Trypanosomiasis) pipeline are assessed.
Chagas Disease (American Trypanosomiasis) R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Chagas Disease (American Trypanosomiasis) discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Chagas Disease (American Trypanosomiasis) companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Chagas Disease (American Trypanosomiasis) pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Chagas Disease (American Trypanosomiasis) Pipeline Market News and Developments during 2020
The Chagas Disease (American Trypanosomiasis) industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Chagas Disease (American Trypanosomiasis) Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
- Chagas Disease (American Trypanosomiasis) pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
- Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
- Company-company partnerships, company-institute partnerships, and investment details of companies are included
- 14 companies are included including AstraZeneca Plc, Bayer AG, Collaborations Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Eisai Co Ltd, Evotec AG, GlaxoSmithKline Plc, IC-MedTech Inc, Novartis AG, Oblita Therapeutics BVBA, RIKEN , Sanofi, Synstar Japan Co Ltd, Selva Therapeutics Inc,
- Disease overview, Pipeline trends, market analysis, and other developments
- Potential licensing/new business opportunities in Chagas Disease (American Trypanosomiasis) pipeline market
- Global coverage of companies and pipeline agents
- 2020 Trends, market analysis, and developments
- Potential growth opportunities
- Comprehensive details of drug candidates
- Drive pipeline research and commercial assessment
- Assess most promising drug candidates and stay ahead of the competition
- Strengthen your pipeline through identifying business expansion and acquisition opportunities
- Develop new candidates based on most focused targets and mechanism of actions
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Chagas Disease (American Trypanosomiasis) Pipeline, 2020
2.2 Most focused Mechanism of Action in Chagas Disease (American Trypanosomiasis) Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Chagas Disease (American Trypanosomiasis) pipeline
2.5 Active Companies Developing Chagas Disease (American Trypanosomiasis) pipeline
3. CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 AstraZeneca Plc
Bayer AG
Collaborations Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Eisai Co Ltd
Evotec AG
GlaxoSmithKline Plc
IC-MedTech Inc
Novartis AG
Oblita Therapeutics BVBA
RIKEN
Sanofi
Synstar Japan Co Ltd
Selva Therapeutics Inc
5. CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2. CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Chagas Disease (American Trypanosomiasis) Pipeline, 2020
2.2 Most focused Mechanism of Action in Chagas Disease (American Trypanosomiasis) Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Chagas Disease (American Trypanosomiasis) pipeline
2.5 Active Companies Developing Chagas Disease (American Trypanosomiasis) pipeline
3. CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 AstraZeneca Plc
Bayer AG
Collaborations Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Eisai Co Ltd
Evotec AG
GlaxoSmithKline Plc
IC-MedTech Inc
Novartis AG
Oblita Therapeutics BVBA
RIKEN
Sanofi
Synstar Japan Co Ltd
Selva Therapeutics Inc
5. CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
